Atractylenolide I

Catalog No.S8291 Batch:S829101

Technical Data

Formula	C₁₅H₁₈O₂
Molecular Weight	230.30	CAS No.	73069-13-3
Solubility (25°C)*	In vitro	DMSO	46 mg/mL (199.73 mM)
		Ethanol	46 mg/mL (199.73 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Atractylenolide I is the major sesquiterpenoid of the rhizome of A. macrocephala and shows a wide spectrum of pharmacological activities such as antiinflammatory, digestion promoting, and antioxidant effects.
In vitro	Atractylenolide I decreases the TNF-α level in LPS-stimulated peritoneal macrophages in a dosedependent manner, IC50=23.1 μM. It also inhibits NO production in LPS-activated peritoneal macrophages, IC50=41 μM. The IC50 of Atractylenolide I for inhibiting the activity of iNOS is 67.3 μM. It shows no marked effects against 5-lipoxygenase (5-LOX) and cyclooxygenase (COX). Atractylenolide I is also reported previously to act on white blood cell membranes and TLR4 and its antiinflammatory activity is related to antagonizing TLR4 ^[1].
In vivo	Atractylenolide I has anti-inflammatory effects. The treatment of Atractylenolide I significantly attenuates LPS-induced lung wet-to-dry weight ratio and MPO activity in LPS-induced acute lung injury mouse. It also significantly inhibits the production of TNF-α, IL-6, IL-1β, IL-13, and MIF production in bronchoalveolar lavage fluid (BALF), as well as neutrophils and macrophages in BALF, upregulates the production of IL-10 in BALF. Atractylenolide I protects mice acute lung injury induced by LPS via inhibition of TLR4 expression and NF-κB activation^[2].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines peritoneal macrophages Concentrations 1-1000 μM Incubation Time 24 h Method 2 × 10⁴ cells per well are plated into 96-well plates, cells/well to a final volume of 200 μL, incubated at 37 °C for 24 h, and given a fresh change of medium. The cells are treated with atractylenolide I (1-1000 μM) dissolved in DMSO, and with LPS (final concentration 10 μg/mL) alone or in combination with atractylenolide I (1–100 μM) dissolved in DMSO. This DMSO percentage allows the optimal solubilization of atractylenolide I in aqueous solution. The control and LPS wells receive the same amount of DMSO. After 24 h of incubation at 37 °C, 20 μL of MTT (5 mg/mL) is added to each well and 4 h later the cells are lysed with 150 μL DMSO. The plate is shaken for 10 min and 30 min later the optical densities (OD570) for atractylenolide I are compared with the OD of the control or LPS stimulated wells to assess the cytotoxicity.
Animal Study:^{^[2]}	Animal Models LPS-induced acute lung injury mouse Dosages 5, 10 and 20 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
peritoneal macrophages
Concentrations
1-1000 μM
Incubation Time
24 h
Method
2 × 10⁴ cells per well are plated into 96-well plates, cells/well to a final volume of 200 μL, incubated at 37 °C for 24 h, and given a fresh change of medium. The cells are treated with atractylenolide I (1-1000 μM) dissolved in DMSO, and with LPS (final concentration 10 μg/mL) alone or in combination with atractylenolide I (1–100 μM) dissolved in DMSO. This DMSO percentage allows the optimal solubilization of atractylenolide I in aqueous solution. The control and LPS wells receive the same amount of DMSO. After 24 h of incubation at 37 °C, 20 μL of MTT (5 mg/mL) is added to each well and 4 h later the cells are lysed with 150 μL DMSO. The plate is shaken for 10 min and 30 min later the optical densities (OD570) for atractylenolide I are compared with the OD of the control or LPS stimulated wells to assess the cytotoxicity.

Animal Study:^{^[2]}

Animal Models
LPS-induced acute lung injury mouse
Dosages
5, 10 and 20 mg/kg
Administration
i.p.

References

Selleck's Atractylenolide I has been cited by 4 publications

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation [ Front Oncol, 2021, 11:738534]	PubMed: 34692516
Atractylenolide‑1 alleviates gastroparesis in diabetic rats by activating the stem cell factor/c‑kit signaling pathway [ Mol Med Rep, 2021, 24(4)691]	PubMed: 34368880
Atractylenolide I Induces Apoptosis and Suppresses Glycolysis by Blocking the JAK2/STAT3 Signaling Pathway in Colorectal Cancer Cells. [ Front Pharmacol, 2020, 26;11:273]	PubMed: 32273843
Lactobacillus Protects Against S. Typhimurium-Induced Intestinal Inflammation by Determining the Fate of Epithelial Proliferation and Differentiation. [ Mol Nutr Food Res, 2020, 64(5):e1900655]	PubMed: 31953989

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.